Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approvals required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”).

The Scheme of Arrangement was subsequently approved by order of the High Court of the Republic of Singapore on July 14, 2026 (Singapore Time), and is expected to become effective after the close of trading on Friday, August 7, 2026 (Eastern Time), upon filing of such court order with the Accounting and Corporate Regulatory Authority of Singapore. As required following the effectiveness of the Redomiciliation, Wave plans to make a series of filings with the Securities and Exchange Commission (“SEC”) after-market on the same day.